Author

admin

Browsing

Genetics is the study of genes, their variations and hereditary characteristics, as well as how these traits are passed on through generations. So what is genetics investing?

When it comes to genetics investing, companies in this niche of the life science sector are mostly focused on four submarkets: DNA sequencing, genetic testing, gene therapy and genomics, which includes gene editing.

This life sciences submarket has gained much attention from investors over the past several years. It has provided a launching pad for a number of biotech firms developing and commercializing novel treatments and drugs addressing a wide range of diseases with unmet needs.

For those looking to dive into the genetics sector, there are numerous investment opportunities to consider. Investing in gene stocks is the most common route, but there are risks due to the market’s volatility, especially when it comes to wins or losses with the US Food and Drug Administration (FDA).

Exchange-traded funds (ETFs) are another popular option for gaining exposure to the industry, and come with less risk than investing in a single stock.

In this article

    What are the key areas of the genetics sector?

    Before diving into investment opportunities in the genetics market, it’s important to understand the industry and the key areas of genetics mentioned above.

      What investors should know about the genetics market

      In the biotech sector, gene therapy is one of the more advanced treatment options, and gene therapy pipeline candidates are robust in late-stage clinical trials.

      In terms of what will — and already has — disrupted the genetics industry, CRISPR gene-editing technology has been on the rise for quite some time. It uses short repeating DNA sequences with “spacers” dividing them to treat genetic diseases.

      While the use of the technology is still in its early stages, in the coming years it’s expected to have a big impact on how genetic diseases are treated, and there are a range of clinical trials underway involving CRISPR technology. So far, the only FDA approved CRISPR-based medicine is Casgevy, developed by Vertex Pharmaceuticals (NASDAQ:VRTX) and CRISPR Therapeutics (NASDAQ:CRSP). It was originally approved in late 2023 for the treatment of sickle cell disease.

      The prominence of gene therapies in the life science sector was a major theme at the 2025 JPMorgan Healthcare Conference in January 2025. Peter Marks, then-director of the FDA’s Center for Biological Evaluation and Research, told attendees that his agency is aiming to accelerate approvals for gene therapies.

      In 2024, the FDA expanded approvals for CRISPR-based Casgevy to beta-thalassemia, and it also approved Pfizer’s (NYSE:PFE) Beqvez and PTC Therapeutics’ (NASDAQ:PTC) Kebilidi.

      Despite experiencing a challenging year in 2024, there is still a lot of optimism in the gene therapy sector. Also speaking at the January conference, Alliance for Regenerative Medicine president Tim Hunt said he believes 10 new cell and gene therapy treatments could reach blockbuster status by 2030.

      “No one’s saying there aren’t headwinds, but we are seeing important signs of growth,” he added.

      Looking at DNA sequencing, this market is driven by advances in biotech, the increasing prevalence of cancer and rising demand for precision medicine, as well as higher investment in research and development. DNA sequencing has become a vital component of this growth and has played a key role in remodeling molecular biology and genomics research.

      Genetic testing is another segment of the genetics industry that is growing at a fast pace. Unsurprisingly, technological breakthroughs have had a huge impact on genetic testing, and so has the fact that governments and regulatory bodies are turning their attention to this market in order to regulate and raise awareness to treat diseases such as cancer, cystic fibrosis and sickle cell anemia.

      Biotech and pharmaceutical companies are also expressing interest in this sector, which is expected to further fuel genetics sector growth in the coming years. Mergers and acquisitions activity is also expected to increase as companies seek to expand their product portfolios new candidates and technologies.

      As can be seen, the genetics industry is vast and complex, but is also ripe with investment opportunities.

      How to invest in gene stocks

      Investors looking to invest in the field of genetics through stocks have many options, from large-cap biotech companies to pure-play gene therapy, gene editing and genetic testing stocks.

      See the list below for genetics companies to consider, and check out the linked stock lists for more options.

      Large-cap gene stocks

      There are a number of large-cap biotech companies that have significant focuses on the field of genomics. Here are a few to consider:

      Amgen (NASDAQ:AMGN)
      A global leader in biotech, Amgen uses advanced human genetics to develop and manufacture therapeutics targeting a variety of diseases with unmet medical needs. The company’s subsidiary deCODE Genetics is researching how human genetic diversity influences disease.

      AbbVie (NYSE:ABBV)
      Research-based global biopharmaceutical company AbbVie that addresses several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology. AbbVie is collaborating with ADARx Pharmaceuticals to develop siRNA therapeutics, viewed as a promising genetic medicine approach for silencing disease-causing genes.

      Regeneron Pharmaceuticals (NASDAQ:REGN)
      Regeneron Pharmaceuticals creates medicines for a wide variety of diseases. The Regeneron Genetics Center is conducting one of the world’s largest genetics sequencing efforts in collaboration with health organizations around the world.

      Gene editing (CRISPR) stocks

      There are a variety of options for investors looking to buy in on the field of gene editing stocks, including:

      CRISPR Therapeutics (NASDAQ:CRSP)
      CRISPR Therapeutics and its partner Vertex Pharmaceuticals co-developed drug Casgevy, a CRISPR/Cas9 genome-edited cell therapy. Casgevy is the first ever treatment based on CRISPR technology to be approved for the US market, as well as by the European Medicines Agency and Health Canada.

      Intellia Therapeutics (NASDAQ:NTLA)
      Intellia Therapeutics is a gene editing biotech company developing drugs for patients with genetic and autoimmune diseases. The company’s drug pipeline includes late-stage clinical programs for therapies targeting hereditary angioedema and transthyretin amyloidosis.

      Vertex Pharmaceuticals (NASDAQ:VRTX)
      Vertex Pharmaceuticals is the other half of the team behind Casgevy. It also offers exposure to other sectors of genomics, with approved treatments for cystic fibrosis and a pipeline of genetic and cell therapies. Its investigational VX-880 islet cell replacement therapy could restore insulin production in patients with type 1 diabetes.

      Gene therapy stocks

      Gene therapy stocks and stem cell stocks are also popular choices for genetics investing. Here are a few to get you started:

      Novartis (NYSE:NVS)
      Switzerland-based Novartis is focused on treatments for a wide range of diseases, including cancers, malaria, leprosy and sickle cell disease. Novartis is developing adeno-associated-virus (AAV)-based and CRISPR-based gene therapies. Its Kymriah treatment was the first CAR-T cell therapy to be approved by the FDA, and the agency also approved its AAV-based therapy Zolgensma.

      Gilead Sciences (NASDAQ:GILD)
      Global biopharmaceutical company Gilead Sciences is advancing breakthrough medicines to prevent and treat serious diseases such as HIV, viral hepatitis and cancer. Its cell-based gene medicine for blood cancer, the CAR T-cell therapy Yescarta, was the second gene therapy approved by FDA.

      uniQure (NASDAQ:QURE)
      Genomic medicine company uniQure develops and markets gene therapy products for patients with severe genetic diseases. The company’s AAV-based gene therapy platform targets liver-directed and central nervous system disorders.

      Genetic testing stocks

      For those interested in genetic testing stocks, these three stocks provide a snapshot on different ways to get exposure to the sector:

      Exact Sciences (NASDAQ:EXAS)
      Exact Sciences focuses on molecular diagnostic tests. The company has developed a molecular screening technology platform called Cologuard that detects a range of cancers, including breast cancer and colorectal cancer.

      Fulgent Genetics (NASDAQ:FLGT)
      A leader in clinical diagnostic genetic sequencing, Fulgent Genetics is a full-service genomics testing company. Its proprietary technology platform, Picture Genetics, allows for the identification of personal DNA health markers in individual patients.

      Illumina (NASDAQ:ILMN)
      Illumina develops, manufactures and markets life science tools and integrated systems that enable the implementation of genomic solutions for the healthcare sector. Its focus is on oncology testing, genetic disease testing, reproductive health and research.

      How to invest in genomics ETFs

      For those who would prefer to invest in the genetics industry overall rather than buying shares in an individual gene stock, investing in genomics ETFs is the way to go. Here are some available ETFs that offer exposure to companies in the biotech and genetics sectors to start you off:

      ARK Genomic Revolution ETF (ARCA:ARKG)
      This ETF tracks firms focused on CRISPR technology, targeted therapeutics, bioinformatics, molecular diagnostics, stem cells and agricultural biology. Its holdings include CRISPR Therapeutics and Guardant Health (NASDAQ:GH).

      Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)
      The Global X Genomics & Biotechnology ETF invests in stocks that are involved in genomic science, which includes gene computational genomics and biotechnology. Its holdings include Illumina and Avidity Biosciences (NASDAQ:RNA).

      iShares Genomics Immunology and Healthcare ETF (ARCA:IDNA)
      The iShares Genomics Immunology and Healthcare ETF focuses on companies involved with genomics, immunology and bioengineering. Its holdings include Regeneron Pharmaceuticals and Arcellx (NASDAQ:ACLX).

      Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

      This post appeared first on investingnews.com

      NEW YORK – The problems with Coco Gauff’s serve have been well-documented, with one of the most basic maneuvers in tennis costing the two-time Grand Slam champion matches.

      But Gauff, who at times was emotional, persevered once again on Thursday night, in front of a packed crowd at Arthur Ashe Stadium. She can put those concerns away for at least one more day, advancing with an error-filled 7-6 (7-5), 6-2 second-round victory over unseeded Donna Vekic of Croatia.

      Gauff moves on to play in the third round against Poland’s Magdalena Fręch.

      Gauff, the No. 3 seed and 2023 US Open champion, had eight double faults and 18 unforced errors, and managed to convert 67% of her first serves in play.

      Gauff got off to a rocky start and was broken on opening serve, which ended in a double fault. She found herself down two games before battling back, breaking Vekic, who had her own issues with her serve, double-faulting three times in the third game alone.

      Vekic, a 2024 Paris Olympics silver medalist, had 10 double faults and 35 unforced errors (mostly balls hit into the net), and received treatment on her right arm from the medical staff. She wasted an opportunity serving for the first set when she was immediately broken, sending the set to a tiebreak, where Gauff’s fewer mistakes were the difference.

      Gauff knows she hasn’t played her best during the first two rounds and needed nearly three hours to beat her first-round opponent, Australian Ajla Tomljanović 6-4, 6-7 (2-7), 7-5, double-faulting 10 times during that match.

      Coco Gauff vs. Donna Vekic result, highlights

      Gauff defeated Vekic 7-6 (7-5), 6-2

      Gauff takes first set in tiebreak

      After receiving treatment on her arm, Vekic served for the first set but was immediately broken, sending the first set to a tiebreak. Neither player got command during the tiebreak, going back and forth with mostly unforced errors, before Gauff settled the issue with a forehand winner and an error by Vekic to take the set 7-6 (5).

      Vekic gets medical treatment

      Vekic is receiving treatment on her right arm from the medical staff and is set to serve for the first set, which has been poorly played with dozens of unforced errors and double faults.

      Vekic struggling with her serve

      Vekic has already double-faulted six times in the first set, including three times in the third game. Gauff failed to take advantage at times and after taking four games in a row after being down 0-2, Vekic has rallied to even up the match.

      Gauff down early

      Gauff’s serve betrayed her to start the match as she was broken, double-faulting to give Vekic the first game. She was blitzed in the second game and will have to dig out of a hole to get back in the match.

      Coco Gauff and Donna Vekic enter stadium court

      Expecting a packed house at Arthur Ashe Stadium as Gauff is introduced to loud applause. Gauff’s serve has been the subject of her game lately, so it will be interesting if she can get off to a good start tonight. Vekic, a 29-year-old from Croatia, is ranked No. 49 in the world and is expected to play aggressively from the start.

      What time is Coco Gauff vs. Donna Vekic?

      Coco Gauff will face off against Donna Vekic in the second-round of the 2025 US Open on Thursday at 7 p.m. ET on Arthur Ashe Stadium at the USTA Billie Jean King National Tennis Center.

      Watch Coco Gauff at the US Open on Fubo

      How to watch Coco Gauff vs. Donna Vekic: US Open TV channel, stream

      • Time: 7 p.m. ET
      • Location: USTA Billie Jean King National Tennis Center (New York)
      • TV: ESPN
      • Streaming: ESPN+, Fubo

      The USA TODAY app gets you to the heart of the news — fast. Download for award-winning coverage, crosswords, audio storytelling, the eNewspaper and more.

      This post appeared first on USA TODAY

      • The Dallas Cowboys have traded Micah Parsons to the Green Bay Packers.
      • Dallas is receiving DT Kenny Clark and two first-round picks from Green Bay.
      • Parsons will receive a four-year, $188 million deal from the Packers.

      The Micah Parsons saga has reached an endpoint that might have seemed unfathomable just weeks ago.

      On Thursday, the Dallas Cowboys agreed to trade the two-time All-Pro edge rusher to the Green Bay Packers in exchange for two first-round picks and defensive tackle Kenny Clark. Parsons, meanwhile, will receive a four-year, $188 million contract that, in addition to making him the NFL’s highest-paid non-quarterback in NFL history, includes $120 million fully guaranteed at signing.

      A massive exchange of resources figures to transform the NFC landscape immediately, with the Packers making an all-out move to reconfigure a flagging pass rush and a Cowboys team that has stubbornly resisted a rebuild now on uncertain ground. But who won the deal?

      Let’s hand out grades for maybe the most consequential move of the NFL offseason:

      Packers trade grade: A-

      Typically, dealing away premium draft picks for highly paid veterans is bad business for NFL teams. Between the selections involved and the massive bill that will accompany Parsons to Wisconsin, the Packers are paying a price that would be prohibitive for almost any player in the league.

      Except, of course, Parsons.

      When it comes to one of the game’s most important tasks in rushing the passer, the three-time finalist for NFL Defensive Player of the Year is very nearly in a class all his own. Of course, he has never won the award that peers T.J. Watt, Myles Garrett and Nick Bosa all have claimed. But Parsons only turned 26 in May, and he’s the only player beyond late legendary pass rusher Reggie White to record at least 12 sacks in each of his first four seasons.

      For that, it’s understandable why a Packers organization known for focusing on home-grown talent would take such a massive swing.

      Jeff Hafley reinvigorated Green Bay’s defense in his first year at the helm, with his aggressive scheme generating big plays and helping the unit rank fifth in yards allowed and sixth in scoring. But with a pass rush win rate that ranked 26th in the NFL, the coordinator seemed to be staring at a ceiling. Parsons should be a force multiplier for Rashan Gary, who could feast in a complementary role, and the rest of the front that Hafley can count on to bring the heat.

      Very few teams are actually one player away from Super Bowl contender status. But Parsons is the rare talent who might put the Packers over the top – or at least keep them at the front of a hypercompetitive first tier of NFC teams. And with an abundance of young talent, Green Bay could afford to take bold action.

      Cowboys trade grade: D+

      Well … that’s it?

      The NFL offseason landscape was largely defined by cooler heads prevailing in heated negotiations, from Myles Garrett’s resolution with the Cleveland Browns to Terry McLaurin landing the long-term contract he sought from the Washington Commanders. Even perhaps the most acrimonious standoff of the summer was at least temporarily defused when Trey Hendrickson and the Cincinnati Bengals found a path forward for 2025.

      Yet somehow Jerry Jones couldn’t manage to de-escalate the bargaining nightmare of his own creation.

      The self-inflicted nature of this clash is the most damning aspect for Dallas. In his departure, Parsons said, ‘I never wanted this chapter to end, but not everything was in my control. … Through it all, I never made any demands. I never asked for anything more than fairness. I only asked that the person I trust to negotiate my contract be part of the process.’

      While contentious contract talks between stars and teams are nothing new, the Cowboys – in typical and unfortunate Jones fashion – took things to another level by repeatedly airing out grievances, particularly regarding agent David Mulugheta’s role in the talks. That didn’t sit well with Parsons, who on Aug. 1 cited ‘repeated shots’ as part of the reason he no longer wished to play for the team.

      Parsons receiving his wish, however, seemed far-fetched until Thursday, when reports indicated the Cowboys were finally listening for deals. With their star pass rusher gone, what are the Cowboys for 2025 and beyond?

      Jones has furiously resisted any notion of a rebuild, unwilling to give off the appearance that his team isn’t clawing its way to end a Super Bowl drought now standing at 30 years. Dallas already appeared to be wading in a sort of no-man’s land for Brian Schottenheimer’s debut season. Now, it’s firmly stuck there.

      With Dak Prescott still claiming the title of the NFL’s highest-paid player thanks to a four-year, $240 million contract extension reached just last year, the Cowboys can’t blow things up. Jones, of course, would never accept that outcome. The acquisition of Clark would seem to reinforce the stubbornness from up top. Sure, there’s been a sizable void at nose tackle for some time. But how does inserting a player who will turn 30 in October move the needle for a defense that now has a massive hole on the edge? Good luck to defensive coordinator Matt Eberflus, who has never been known as a heavy blitzer but will have to concoct some innovative ways to generate pressure with what now looks to be a pretty suspect group.

      The two first-round picks are nothing to sneeze at, but barring an injury to Jordan Love, the Packers likely are only turning over choices in the mid-20s. If Jones expects this trade to reboot his franchise, he’s very likely overconfident in his own personnel preferences.

      Jones has pushed back on many of the emerging narratives about his priorities. In an exclusive interview with USA TODAY Sports’ Jarrett Bell, he discussed the franchise’s astronomical value and popularity by saying, ‘I explain it by hard work. I bust my ass. This exact same hard work that is going on in the football. I work my ass off.’

      Maybe it’s not Jones’ effort that’s worth questioning. In this case – and many others – though, he’s hustling backward.

      This post appeared first on USA TODAY

      The shocking Micah Parsons trade is reminiscent of another blockbuster deal the Dallas Cowboys made over three decades ago.

      Go all the way back to 1989. When Jerry Jones and the Cowboys traded running back Herschel Walker, at the peak of his career, to the Minnesota Vikings in exchange for five players and six draft picks. The Cowboys would use their draft assets on players such as Emmitt Smith, Darren Woodson and Russell Maryland. The trade was genesis of their 90s dynasty. They would go on to win three Super Bowls in the decade.

      The Cowboys haven’t sniffed a Super Bowl since. Not even an NFC championship game appearance.

      Cowboys trade Micah Parsons to Packers in blockbuster

      Perhaps Jones harken back to his gamble in 1989 that was paid off by Super Bowl jewelry before he greenlit Thursday’s trade that sent another franchise player packing.

      The Cowboys got defensive tackle Kenny Clark and two first-round picks in exchange for Parsons. Time will reveal the players the Cowboys get with their newly-acquired picks, though, they are expected to be late first-round selections because Parsons and the Packers should be good. Dallas could get a Hall of Famer out of the draft like Smith. Or Pro Bowl-caliber players similar to Woodson and Maryland.

      But this trade doesn’t feel like it’ll yield the same results.  

      Parsons won Defensive Rookie of the Year in 2021, he’s a two-time first-team All-Pro and a four-time Pro Bowler, who at 26 years old might not even be in his prime yet.

      Parsons produced 52.5 sacks in his first four seasons. He and Hall of Famer Reggie White are the only two players in NFL history to compile 12 or more sacks in their first four NFL seasons. The Cowboys defense ranked first in defensive EPA per play when Parsons was on the field since 2021. When Parsons wasn’t on the field, the Cowboys ranked last.

      The Cowboys traded a generational defensive player in the aftermath of a 7-10 season.

      Maybe the biggest loser in the trade is Dallas sports fans.

      Within a calendar year, the Dallas Mavericks traded Luka Dončić to the Los Angeles Lakers and the Cowboys dealt Parsons to the Packers.

      Micah Parsons trade grades: Who won deal between Packers, Cowboys?

      Two franchise cornerstones in their respective sports and fan favorites are gone. Sorry Dallas sports fans.

      The Mavs appear to have made out well from their trade, aided by the NBA draft lottery and subsequent No. 1 overall pick, Cooper Flagg. The Cowboys are to be determined. But Thursday’s blockbuster trade feels like a major step back for the Cowboys and a simultaneously signals a rebuild for the franchise.

      This post appeared first on USA TODAY

      Kyle Schwarber could not be stopped against the Braves.

      The Philadelphia Phillies slugger launched four home runs against Atlanta on Aug. 28, bringing his season total up to 49. Only the Seattle Mariners’ Cal Raleigh (50) has hit more this season.

      Schwarber hit a solo homer in the first inning, a two-run shot in the fourth inning, a three-run shot in the fifth inning and another three-run shot in the seventh inning of the Phillies’ 19-4 win. His final line: an incredible 4-for-6 with nine RBIs, a Phillies record per MLB.

      He homered off three of the Braves’ four pitchers: starter Cal Quantrill and relievers Austin Cox (twice) and Wander Suero.

      Schwarber had a chance to become the first player to hit five homers in a game, but his final at-bat in the eighth inning ended in a pop-out.

      This marks just the 21st four-homer game in MLB history, though incredibly three have come this season. Athletics rookie Nick Kurtz did it last month and Eugenio Suarez did it in April, also against the Braves. Prior to this season, there hadn’t been a four-homer game since 2017.

      Watch: Kyle Schwarber hits four homers vs. Braves

      This story has been updated with new information.

      The USA TODAY app gets you to the heart of the news — fastDownload for award-winning coverage, crosswords, audio storytelling, the eNewspaper and more.

      This post appeared first on USA TODAY

      The Dallas Cowboys and Green Bay Packers reached an agreement on a blockbuster trade Thursday involving Micah Parsons.

      The Cowboys will send Parsons, a 26-year-old star pass rusher who recorded 52.5 sacks during his four seasons in Dallas, to the Packers. In return, Dallas will receive two future draft picks along with veteran defensive lineman Kenny Clark.

      However, just moments before the deal was announced Cowboys legend and Hall of Famer Michael Irvin was on live television publicly declaring that no trade involving Parsons would take place.

      ‘I guarantee Micah Parsons is not going anywhere,’ Irvin declared.

      The NFL on ESPN’s X post about Irvin’s comments was made at 4:59 p.m. ET. Ian Rapoport reported the trade just one minute later, at 5:00 p.m. In less than a minute, Irvin’s confident ‘guarantee’ became one of the coldest takes in history.

      In Irvin’s defense, ESPN’s post on X may have been one minute before the trade was first reported, but the ‘NFL Live’ segment could have been aired earlier. And many expected Parsons to agree to an extension, rather than being shipped out of Dallas.

      Parsons was seeking a new contract and got one with the Packers, agreeing to a four-year, $188 million extension deal with Green Bay, including $136 million guaranteed, making him the new highest-paid non-quarterback in NFL history.

      Either way, Irvin’s bold statement became a viral moment in the latest Earth-shattering moment across the NFL.

      This post appeared first on USA TODAY